Rate of return on novel drugs

New studies by academic economists bolster the case for providing American senior citizens with a prescription drug benefit while suggesting that price controls and other policies that stifle pharmaceutical innovation are not cost-effective.

Two healthcare economists who are pioneering efforts to sort out the costs and benefits of pharmaceuticals presented the findings at a recent workshop in Washington. ...